Insilico Medicine
An AI-driven biopharmaceutical company focused on computational drug discovery and generative AI-based drug research and development.
Core Facts
Timeline (last 90 days)
The life sciences AI track includes protein structure prediction represented by DeepMind's AlphaFold series, computational drug discovery represented by Schrödinger and Insilico Medicine, and general research assistants, among other categories.
Insilico Medicine's rentosertib had the TNIK target identified by the PandaOmics target discovery platform and the small molecule designed by the Chemistry42 generative chemistry system, and the company describes it as the first candidate drug in which AI led both target discovery and molecular design.
The Phase IIa trial of rentosertib for idiopathic pulmonary fibrosis enrolled 71 patients, and the results were published in Nature Medicine in June 2025, meeting the primary safety endpoint, with the 60 mg once-daily group showing a mean increase in forced vital capacity of 98.4 mL over 12 weeks versus a decrease of 20.3 mL in the placebo group, and the drug has since advanced to Phase III.
Insilico Medicine reported in 2025 the Phase 2a clinical trial results of an AI-discovered drug for pulmonary fibrosis.
The anti-fibrotic drug designed by Insilico Medicine using AI entered clinical trials in just 30 months, 5 years faster than the traditional process.
A drug candidate designed from scratch by Insilico Medicine using AI has entered Phase II clinical trials.
All Facts (8)
Insilico Medicine uses AI to compress the drug candidate discovery cycle from years to months.
75%UnverifiedInsilico Medicine于2023年将其AI设计的候选药物推进至临床II期试验，成为首个完全由AI设计并进入临床阶段的药物分子
80%UnverifiedThe life sciences AI track includes protein structure prediction represented by DeepMind's AlphaFold series, computational drug discovery represented by Schrödinger and Insilico Medicine, and general research assistants, among other categories.
50%UnverifiedInsilico Medicine's rentosertib had the TNIK target identified by the PandaOmics target discovery platform and the small molecule designed by the Chemistry42 generative chemistry system, and the company describes it as the first candidate drug in which AI led both target discovery and molecular design.
50%UnverifiedThe Phase IIa trial of rentosertib for idiopathic pulmonary fibrosis enrolled 71 patients, and the results were published in Nature Medicine in June 2025, meeting the primary safety endpoint, with the 60 mg once-daily group showing a mean increase in forced vital capacity of 98.4 mL over 12 weeks versus a decrease of 20.3 mL in the placebo group, and the drug has since advanced to Phase III.
50%UnverifiedThe anti-fibrotic drug designed by Insilico Medicine using AI entered clinical trials in just 30 months, 5 years faster than the traditional process.
50%UnverifiedA drug candidate designed from scratch by Insilico Medicine using AI has entered Phase II clinical trials.
50%UnverifiedInsilico Medicine reported in 2025 the Phase 2a clinical trial results of an AI-discovered drug for pulmonary fibrosis.
50%